Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor ...Middle East

PR Newswire - News
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor
BEIJING, Aug. 2, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 in China. JAB-21822 is Jacobio's innovative in-house small molecule anti-cancer drug, which is designed to...

Hence then, the article about jacobio announces first patient dosed in phase i ii clinical trial of kras g12c inhibitor for solid tumor was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor )

Apple Storegoogle play

Last updated :

Also on site :